SOUTH SAN FRANCISCO, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock. The stock was sold at a price to the public of $6.75 per share, for aggregate gross proceeds of approximately $63.3 million, from the company’s existing shelf registration statement. The shares include 1,222,500 shares of common stock sold pursuant to an over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. Net proceeds from the offering were approximately $59.1 million after deducting underwriting discounts and commissions and the estimated expenses of the offering. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies, and to fund possible investments in or acquisitions of complementary businesses, products, or technologies.
Piper Jaffray and UBS Investment Bank acted as joint book-running managers for the offering. BTIG and Janney Montgomery Scott acted as co-managers.
A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 8, 2017, amended on April 28, 2017 and declared effective by the SEC on May 2, 2017. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by phone at 1-800-747-3924, or by email at firstname.lastname@example.org, and from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, 25th floor, New York, NY 10019, or by phone at 888-827-7275 or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Vice President, Investor Relations